#76 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Suzetrigine’s demonstrated safety profile and ability to reduce postoperative opioid requirements offers clinicians a non-opioid analgesic option that could decrease opioid exposure and associated risks like addiction and overdose. This is particularly relevant given that postoperative pain management remains a major driver of opioid initiation in opioid-naive patients, and alternative agents with efficacy could reshape standard perioperative protocols. Clinicians should monitor emerging data on how suzetrigine compares to cannabis or combination approaches for patients seeking to minimize opioid consumption while maintaining adequate pain control.
Suzetrigine, a selective sodium channel blocker, demonstrated safety and tolerability in clinical trials with no serious adverse events, and emerging data suggest that combining cannabis with opioids may reduce postoperative opioid requirements in pain management. This finding is clinically significant because it addresses the critical need to minimize opioid exposure in the perioperative setting, where excessive opioid use contributes to dependence and overdose risk. The potential synergistic effect between cannabis-derived compounds and traditional opioids could offer an alternative multimodal analgesic strategy for surgeons and anesthesiologists managing acute postoperative pain. However, clinicians should recognize that cannabis-opioid combinations remain understudied in many patient populations and regulatory frameworks vary significantly by jurisdiction, requiring careful patient selection and informed consent. The practical takeaway is that as evidence accumulates on adjunctive cannabis use for acute pain, clinicians should stay informed about local regulations and consider cannabis as part of a comprehensive opioid-sparing pain management strategy while awaiting larger prospective trials.
“What suzetrigine’s postoperative data tells us is that we finally have another non-opioid tool in our toolkit, and that matters clinically because it means fewer patients will need opioids after surgery, which is where many addiction journeys begin. Cannabis alone hasn’t proven sufficient for acute surgical pain in controlled trials, but compounds like suzetrigine give us a real alternative to reach for before we ever consider opioids or combination therapies.”
🩺 The emergence of selective sodium channel blockers like suzetrigine as adjunctive analgesics offers a potential pharmacological pathway to reduce postoperative opioid requirements, addressing a critical gap in multimodal pain management. However, clinicians should recognize that opioid-sparing strategies remain context-dependent, varying substantially based on surgical type, patient comorbidities, baseline pain tolerance, and access to regional anesthesia techniques already well-established in practice. The mention of cannabis-opioid combinations in the article’s scope warrants particular caution, as evidence for cannabis analgesia remains inconsistent, cannabis-opioid interactions are incompletely characterized, and cannabis products carry regulatory and legal variability that complicates integration into standard perioperative protocols. Rather than viewing suzetrigine or other novel agents as replacements for proven multimodal approaches already in use, clinicians should consider them as incremental tools
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
